妊娠期阿司匹林最佳剂量、剂型及时间治疗学的药代动力学评估
本研究纳入12例高危孕妇和3例非妊娠妇女,比较阿司匹林活性代谢物水杨酸的药代动力学。妊娠期100 mg阿司匹林时曲线下面积降低40%±4%、峰浓度降低29%±3%、清除率增加44%±8%;150 mg可减小曲线下面积降幅。肠溶片较非肠溶片达峰延迟4小时、峰浓度降低47%±3%、表观分布容积增加48%±1%,总曲线下面积无差异;早晚给药无差异。
要点
- 妊娠期阿司匹林100 mg时总代谢物暴露降低、清除率增加,可能需要调整剂量。
- 妊娠期使用150 mg阿司匹林可使曲线下面积更接近非妊娠妇女100 mg的水平。
- 肠溶片与非肠溶片总暴露无差异,但肠溶片达峰延迟、峰浓度降低;早晚给药无差异。
核心结论
- 妊娠期阿司匹林总药物代谢物浓度降低,可能需要对孕妇进行剂量调整。
- 这一降低可能源于妊娠期阿司匹林清除率增加所致的药代动力学改变。
- 肠溶与非肠溶阿司匹林之间、早晨与晚间给药之间的总药物代谢物浓度无差异。
- 需要进一步的药效学和临床研究来检验这些药代动力学发现的临床相关性。
研究设计与样本
- 研究纳入12例高危孕妇和3例非妊娠妇女。
- 孕妇分为4组:100 mg肠溶片、100 mg非肠溶片、150 mg非肠溶片早晨给药、150 mg非肠溶片晚间给药。
- 非妊娠妇女依次完成全部4种给药方案,每种方案之间至少洗脱30天。
- 在基线(服药前)及服药后1、2、4、6、12、24小时采集血样,用液相色谱-质谱法测定水杨酸水平。
- 采用SPSS v25软件分析曲线下面积(0至24小时)、峰浓度、达峰时间、表观分布容积、清除率和消除半衰期的统计学显著性。
主要发现
- 给予100 mg阿司匹林时,孕妇较非妊娠妇女曲线下面积(0至24小时)降低40%±4%(P<.01),峰浓度降低29%±3%(P<.01),清除率增加44%±8%(P<.01)。
- 孕妇使用150 mg阿司匹林时,曲线下面积(0至24小时)的降低幅度减小,其曲线下面积更接近非妊娠妇女使用100 mg阿司匹林所达到的水平。
- 与100 mg非肠溶片相比,100 mg肠溶片达峰时间延迟4小时(P<.01),峰浓度降低47%±3%(P<.01),表观分布容积增加48%±1%(P<.01),总曲线下面积无差异。
- 早晨给药与晚间给药的阿司匹林药代动力学无差异。
局限性
- 需要进一步的药效学和临床研究来检验这些药代动力学发现的临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benefit of aspirin in preventing preeclampsia is well established; however, studies over the years have demonstrated variability in outcomes with its use. Potential contributing factors to this variation in efficacy include dosing, time of dosing, and preparation of aspirin. OBJECTIVE: We aimed to compare the difference in pharmacokinetics of aspirin, through its major active metabolite, salicylic acid, in pregnant women and nonpregnant women, and to examine the effect of dose (100 mg vs 150 mg), preparation (enteric coated vs non-enteric-coated), and chronotherapy of aspirin (morning vs evening) between the 2 groups. MATERIALS AND METHODS: Twelve high-risk pregnant women and 3 nonpregnant women were enrolled in this study. Pregnant women were in 1 of 4 groups (100 mg enteric coated, 100 mg non-enteric-coated, 150 mg non-enteric-coated morning dosing, and 150 mg non-enteric-coated evening dosing), whereas nonpregnant women undertook each of the 4 dosing schedules with at least a 30-day washout period. Blood samples were collected at baseline (before ingestion) and at 1, 2, 4, 6, 12, and 24 hours after ingestion of aspirin. Plasma obtained was analyzed for salicylic acid levels by means of liquid chromatography-mass spectrometry. Pharmacokinetic values of area under the curve from time point 0 to 24 hours point of maximum concentration, time of maximum concentration, volume of distribution, clearance, and elimination half-life were analyzed for statistical significance with SPSS v25 software. RESULTS: Pregnant women had a 40% ± 4% reduction in area under the curve from time point 0 to 24 hours (P < .01) and 29% ± 3% reduction in point of maximum concentration (P < .01) with a 44% ± 8% increase in clearance (P < .01) in comparison to that in nonpregnant women when 100 mg aspirin was administered. The reduction in the area under the curve from time point 0 to 24 hours, however, was minimized with the use of 150 mg aspirin in pregnant women, with which the area under the curve from time point 0 to 24 hours was closer to that achieved with the use of 100 mg aspirin in nonpregnant women. There was a 4-hour delay (P < .01) in the time of maximum concentration, a 47% ± 3% reduction in point of maximum concentration (P < .01) and a 48% ± 1% increase in volume of distribution (P < .01) with the use of 100 mg enteric-coated aspirin compared to non-enteric-coated aspirin, with no difference in the overall area under the curve. There was no difference in the pharmacokinetics of aspirin between morning and evening dosing. CONCLUSION: There is a reduction in the total drug metabolite concentration of aspirin in pregnancy, and therefore a dose adjustment is potentially required in pregnant women. This is likely due to the altered pharmacokinetics of aspirin in pregnancy, with an increase in clearance. There was no difference in the total drug metabolite concentration of aspirin between enteric-coated and non-enteric-coated aspirin and between morning and evening dosing of aspirin. Further pharmacodynamic and clinical studies are required to examine the clinical relevance of these pharmacokinetic findings.
引用
- Shanmugalingam R, Wang X, Münch G, et al. A pharmacokinetic assessment of optimal dosing, preparation, and chronotherapy of aspirin in pregnancy. Am J Obstet Gynecol. 2019. PMID: 31051121. doi:10.1016/j.ajog.2019.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。